Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Dood dreigt voor 1,5 miljoen mensen Myanmar
Volgen
BANGKOK - Voor anderhalf miljoen mensen in Myanmar (Birma) die door orkaan Nargis zijn getroffen, dreigt de dood als ze niet snel de beschikking krijgen over schoon water en sanitaire voorzieningen. Dat heeft Sarah Ireland, regiodirecteur Oost-Azië van de hulporganisatie Oxfam, zondag gezegd. "Meer dan 100.000 mensen zijn waarschijnlijk omgekomen en alles duidt op een grotere catastrofe", aldus Ireland, die vanuit Thailand reageerde. Ze stelde dat het dodental kan oplopen tot het vijftienvoudige van wat het nu is. Vervuild Ireland liet weten dat het dodental stijgt door gebrek aan voedsel en omdat mensen vervuild water moeten drinken. Ze waarschuwde voor de uitbraak van ziektes als cholera en tyfus. Rode Kruis Inmiddels is een vliegtuig met aan boord 35 ton hulpgoederen van het Internationale Rode Kruis zondag in de hoofdstad Yangon van Myanmar aangekomen. Dat heeft het Rode Kruis in een verklaring laten weten. Het materiaal is bestemd voor de mensen die zijn getroffen door de cycloon Nargis. Het vliegtuig vervoerde onder meer een voorraad medicijnen waarmee gedurende drie maanden aan 10.000 mensen een basisgezondheidszorg kan worden verleend. Verder heeft het Rode Kruis aan Myanmar een mobiele machine voor het zuiveren van water verstrekt.
De Samenwerkende Hulporganisaties (SHO) hebben gironummer 555 opengesteld voor de slachtoffers van de cycloon Nargis in Myanmar. De SHO is een samenwerkingsverband van acht Nederlandse hulporganisaties. Bij grote rampen werken zij samen in een Nationale Actie, dit keer onder de slogan 'Help de slachtoffers cycloon Myanmar!'.www.giro555.nl/nl-NL/default.aspx ….en nu de junta een schop onder de kont!www.nytimes.com/2008/05/10/world/asia... www.youtube.com/watch?v=Z72Uv-qMci0 And love is not the easy thing The only baggage you can bring... And love is not the easy thing... The only baggage you can bring Is all that you can't leave behind And if the darkness is to keep us apart And if the daylight feels like it's a long way off And if your glass heart should crack And for a second you turn back Oh no, be strong Walk on, walk on What you got they can�t steal it No they can�t even feel it Walk on, walk on... Stay safe tonight You're packing a suitcase for a place none of us has been A place that has to be believed to be seen You could have flown away A singing bird in an open cage Who will only fly, only fly for freedom Walk on, walk on What you've got they can't deny it Can�t sell it, can�t buy it Walk on, walk on Stay safe tonight And I know it aches And your heart it breaks And you can only take so much Walk on, walk on Home... hard to know what it is if you�ve never had one Home... I can�t say where it is but I know I'm going home That's where the hurt is I know it aches How your heart it breaks And you can only take so much Walk on, walk on Leave it behind You've got to leave it behind All that you fashion All that you make All that you build All that you break All that you measure All that you steal All this you can leave behind All that you reason All that you sense All that you speak All you dress up All that you scheme...
Grand Cru schreef:
Ze waarschuwde voor de uitbraak van ziektes als cholera en tyfus.
Dukoral Dukoral® is an oral vaccine with a documented protective effect against diarrhea caused by cholera. The vaccine stimulates a protective immune response in the gut and has demonstrated a protective efficacy against cholera of approximately 85%. The vaccine is suitable for travelers and is indicated for use in adults and children over two years of age. Pregnant and lactating women may use it. Dukoral® was first licensed in 1992 and is licensed in over 50 countries. It is presently the only internationally licensed oral cholera vaccine. To date, over 9 million doses of Dukoral® have been supplied with very few adverse events reported. Cholera is an acute intestinal infection often caused by eating food or drinking water contaminated with the Vibrio cholerae bacteria. In its most severe form, the disease can cause a sudden onset of acute watery diarrhea that can lead to severe dehydration, kidney failure and ultimately death if treatment is not promptly given. Most people infected with cholera do not develop any symptoms, although the bacterium is present in their feces for 7-14 days, potentially infecting other individuals. Morbidity and mortality Cholera remains a global threat, particularly in developing countries where access to safe drinking water and adequate sanitation cannot be guaranteed. The number of cholera cases reported to the WHO in 2006 was close to 240 000 cases, including approximately 6300 deaths. It is likely the morbidity and mortality caused by V. cholerae is grossly underreported – less than 10% - to the WHO. As a result, the true burden of this disease is severely underestimated. Geographical distribution Cholera remains a global threat. Almost every developing country, where poor sanitary conditions prevail, faces cholera outbreaks and the threat of a cholera epidemic. Altogether seven cholera pandemics have been reported. The latest, still ongoing pandemic started in Indonesia in 1961, spreading to Africa in 1971 and to the Americas in 1991. Cholera is considered endemic in many countries. Transmission Cholera is spread by fecal contamination of water and food, linked to poor sanitation. Person-to-person transmission of cholera is rare. Symptoms About 75% of people infected with cholera do not develop symptoms. Of those who do develop symptoms, 80% are considered mild to moderate cases and 10 to 20% are severely affected. Children and the elderly are most susceptible. Symptoms include acute, profuse watery diarrhea (“rice-water stools”) and often vomiting. Tachycardia, loss of skin turgor, dry mucous membranes, hypotension and thirst are often signs of dehydration. In extreme cases and if left untreated, severe dehydration can lead to kidney failure and death. Cholera is one of the most rapidly fatal infectious illnesses known. Treatment and prevention Rehydration is the key form of treatment. Mild or moderate dehydration can be treated with simple oral rehydration solutions containing salts and glucose. Severe cases of dehydration require treatment with intravenous fluids and antibiotics. WHO recommends that antibiotics are only used in severe cases as overuse of antibiotics has led to the emergence of multiresistant strains, some of which where found to be highly virulent. Cholera can be prevented through the provision of clean water and proper sanitation. For travelers to endemic areas, it is recommended to “boil it, cook it, peel it, or forget it” and to avoid eating high-risk foods. An internationally licensed oral vaccine is currently available on the market and is suitable for travelers. In 2006, WHO published official recommendations for oral vaccines use in complex emergencies.
Tyfus is een uitputtende en levensgevaarlijke ziekte die door de S. Typhi bacterie wordt veroorzaakt. Paratyfus is vergelijkbaar met Tyfus maar het ziektebeeld is over het algemeen milder. Paratyfus wordt veroorzaakt door de serotypen van S. Paratyphi A, B of C. Elk jaar krijgen ongeveer 16 miljoen mensen Tyfus. In de endemische gebieden komt Tyfus het meest voor bij kinderen tussen de 5 en 19 jaar. Geografische spreiding Tyfus komt in de meeste delen van de wereld voor behalve in geïndustrialiseerde gebieden zoals de Verenigde Staten, Canada, westelijk Europa, Australië, en Japan. In deze landen hebben de juiste sanitaire faciliteiten de ziekte vrijwel geëlimineerd. De meeste ziektegevallen die in geïndustrialiseerde landen worden gemeld zijn gerelateerd aan reizigers naar endemische gebieden zoals Afrika, Azië (behalve Japan) en Latijns-Amerika. Daarom zouden de mensen die naar deze gebieden reizen, voorzorgsmaatregelen tegen de ziekte moeten overwegen. Overdracht Tyfus wordt over het algemeen overgedragen via de ontlasting - mond route, door verontreiniging van voedsel of water, of door persoonlijk contact. Het overdragen van de ziekte is vaak het gevolg van slechte hygiëne en slechte sanitaire voorzieningen. Iemand kan de bacterie bij zich dragen en verspreiden zonder de ziekte symptomen te ervaren. Volgens de Centers for Disease Control and Prevention (CDC), blijven 5% van mensen die tyfus hebben gehad drager van de bacterie. Symptomen De symptomen van tyfus zijn koorts, maagpijn, gewichtsverlies, verlies van eetlust, delirium, erge diarree (bij kinderen) en constipatie (bij volwassenen). De personen met tyfus hebben gewoonlijk een hoge aanhoudende koorts van 39 tot 40 °C. Soms hebben de patiënten vlakke, dieproze gekleurde vlekken op de huid. Bij een klassiek verlopend ziektebeeld zijn er twee fasen te onderscheiden na een gebruikelijke incubatieperiode van 7-14 dagen: Eerste fase: de temperatuur neemt geleidelijk toe tot 40 °C, met periodes van zweten, verlies van eetlust, hoesten en hoofdpijn. Constipatie en huid afwijkingen kunnen de duidelijkste symptomen zijn. Kinderen kunnen vaak braken en diarree hebben. Deze fase duurt ongeveer een week, met toenemende lusteloosheid en een minder scherp bewustzijn. Tweede fase: in de tweede tot derde week van de ziekte, ontwikkelen zich de symptomen van de maagdarm besmetting. De koorts blijft hoog en de polsslag wordt zwak en snel. In de derde week wordt de constipatie vervangen door erwtensoep-achtige diarree. De ontlasting kan bloed bevatten. In de vierde of vijfde week zakt de koorts en verbetert de algemene conditie langzaam. Behandeling en preventie Tyfus is over het algemeen goed te behandelen met een intensieve antibiotica kuur. Gemiddeld duurt de behandeling 18 dagen en worden er 60 tabletten antibiotica ingenomen. Omdat intensief antibiotica gebruik in verband gebracht wordt met resistentie ontwikkeling gaat de voorkeur ernaar uit om met vaccinatie, voorzorgmaatregelen en verbetering van hygiëne en sanitaire voorzieningen de verspreiding van de ziekte te controleren. Voor reizigers naar endemische landen betekent dat naast vaccinatie strikte aandacht voor voedsel en water. Vivotifwww.crucell.nl/page/downloads/Bijslui...
WHO, Cyclone Nargis: Myanmar Vaccination recommendations: Essential: Diptheria 10 years Can be combined with tetanus Tetanus 10 years Booster dose is recommended if not taken in the last 10 years Polio 10 years Potential risk of importation of wild virus with displaced populations. Typhoid 3 years Hepatitis A life If there is no proof of immunity by vaccine or illness, even if departure at short notice. Can be combined with Hepatitis B Hepatitis B 15 years Cholera 6 months If there is sufficient time to receive the 2 oral doses to be taken at one week interval before departure. (Immunity is obtained one week after the second dose of a combination Oral cholera & ETEC (enterotoxigenic, E.Coli) vaccine (Brand name DUKORAL). Given the structural damage caused by the cyclone and flooding of water supplies there is an additional risk of waterborne diseases affecting large numbers of the urban, rural and displaced populations. In addition, extensive damage to infrastructure and distribution systems, as well as power supplies, will make it virtually impossible to prepare food safely, posing an additional risk of foodborne diseases. Chlorine powder, water purification units, plastic sheeting for shelter, cooking utensils, ready-to-eat survival food rations, essential medicines, cholera kits, antimalarial drugs, long lasting insecticide-treated bednets and supplies for the management of corpses are urgently needed. The populations affected by the cyclone in Myanmar are at immediate risk from outbreaks of waterborne and foodborne diseases, particularly cholera, typhoid, Shigella dysenteriae type 1(Sd1). There is increasing evidence of significant antimicrobial resistance, including multi-drug resistance (resistance to more than three antimicrobials) in Sd1 isolates from the region. Cholera and shigellosis are endemic in the region. Usual water sources can become unsafe for drinking for several reasons: the incursion of floodwaters, faecal contamination caused by overflow of latrines, inadequate sanitation and upstream contamination of interconnected water sources.
Cholera: Disease of disaster Friday, May 9, 2008 In the days after Cyclone Nargis sent a wall of seawater through Burma's low-lying Irrawaddy Delta in May 2008, the threat of disease became a major concern for survivors. The United Nations estimated that at least 1.5 million people were "severely affected," needing food, shelter and clean drinking water. Clean drinking water is especially critical in the wake of a disaster of this magnitude. Without it, people begin to dehydrate within a few days. And with seawater and large numbers of decomposing bodies overwhelming water supplies, disease quickly becomes a threat. Among the most common diseases to hit areas where drinking water is compromised is cholera. What is cholera? Cholera is an intestinal infection caused by the bacterium Vibrio cholerae. You get it from drinking Refugee girls fetch water from a hand well in Kabul, Afghanistan. More than 2,000 suspected cases of cholera detected in the Afghan capital in June 2005. At least eight people have died. (Tomas Munita/Associated Press) contaminated water or eating contaminated food. About five per cent of infected people will become severely ill and will develop profuse watery diarrhea, vomiting, and leg cramps. In severely ill people, cholera will cause rapid dehydration and shock. If you have a severe case and you are not treated, you could die within a few hours. However, most people who are infected don't get sick, although the bacterium can be present in their feces for up to two weeks. Of those who do get sick, 80-90 per cent of cases are either mild or moderate and often indistinguishable from other types of acute diarrhea. How prevalent is cholera? According to the World Health Organization, there were at least 236,896 cases of cholera in 52 countries in 2006. After years of declines, the number of cases rose dramatically in 2006 to levels not seen since the 1990s. All but 2,000 of those cases were reported in Africa. The number of deaths in 2006 was 6,306 — three times the number recorded a year earlier. How is cholera treated? Rehydrating the patient is the most effective way of treating someone with severe cholera. There are at least two ways of doing this: • By drinking large quantities of a rehydration solution — a prepackaged mixture of sugar and salts that can be mixed with clean water. • By intravenously replacing lost fluids, in severe cases. Antibiotics may also be used in an effort to shorten the course and the severity of the illness. But antibiotics are not as critical in the treatment as rehydration. Is cholera just a risk in areas hit by disaster? Cholera is a risk anywhere that hygiene and access to clean drinking water is a problem. It was not uncommon in North America in the 1800s, but it has been rare in industrialized countries for the past 100 years or so. Cholera remains a threat in many developing countries. There have been a few cases in Canada over the past several years, but they have all involved travellers returning from countries where cholera was present. How do I protect myself? The best way to ensure that you do not get infected is to practise good personal hygiene and make sure you drink clean water. If you have doubts about the drinking water, stick to bottled water or water that you have boiled or treated with chlorine or iodine. Eat only foods that have been thoroughly cooked and are still hot. There are two oral vaccines available. Dukoral offers some protection against traveller's diarrhea for up to three months. Mutachol is partially effective against one strain of cholera. The U.S. Centers for Disease Control does not recommend oral cholera vaccines, nor does the World Health Organization — UNDER NORMAL CIRCUMSTANCES. Reasons cited include: • The risk of contracting the disease for travellers is low. • The vaccines are expensive. • The vaccines offer limited protection. However, the WHO does recommend pre-emptive use of oral cholera vaccines in emergency situations. The trick is getting enough of the vaccine to stricken areaswww.cbc.ca/health/story/2008/05/09/f-... JonnyBlazze wrote:Posted 2008/05/10 at 7:28 PM ET If the world stands by and allows this (cholera) to happen; then as humans we are as pathetic as the junta.
flosz schreef:
There are two oral vaccines available. Dukoral offers some protection against traveller's diarrhea for up to three months. Mutachol is partially effective against one strain of cholera.
Dokoral = SBL Mutachol = Berna
aragana schreef:
[quote=flosz]
There are two oral vaccines available. Dukoral offers some protection against traveller's diarrhea for up to three months. Mutachol is partially effective against one strain of cholera.
[/quote]
Dokoral = SBL
Mutachol = Berna
Het tuig van het regime in Birma laat haar bevolking liever verrotten dan dat ze vacinatie accepteren.
aragana schreef:
Dukoral = SBL
Mutachol = Berna
.......oraler attenuierter Impfstoff (Orochol®): seit 2004 weltweit nicht mehr am Markt www.lgl.bayern.de/aktuell/veranstaltu... crucell.yourbb.nl/viewtopic.php?f=9&t... Orochol=Mutachol
flosz schreef:
[quote=aragana]
Dukoral = SBL
Mutachol = Berna
[/quote]
.......oraler attenuierter Impfstoff (Orochol®): seit 2004 weltweit
nicht mehr am Markt
www.lgl.bayern.de/aktuell/veranstaltu... crucell.yourbb.nl/viewtopic.php?f=9&t... Orochol=Mutachol
Vaccines for Cholera Control: Does Herd Immunity Play a Role Lorenz von Seidlein Funding: The author received no funding for this article. Competing interests: The author has in the past received funding from International Vaccine Institute and from World Health Organization. Citation: von Seidlein L (2007) Vaccines for Cholera Control: Does Herd Immunity Play a Role. PLoS Med 4(11): e331 doi:10.1371/journal.pmed.0040331 Currently two cholera vaccines are internationally licensed: (1) Dukoral, consisting of inactivated whole cells of V. cholerae O1 combined with the B-subunit (BS-WC) of the cholera toxin, and (2) the live attenuated vaccine CVD 103HgR (Orochol or Mutacol). Both vaccines have an excellent safety profile and afford high rates of protection over several years. The companies producing each vaccine have been acquired in the last two years by the publicly listed Dutch company Crucell. Only Dukoral is currently produced, and for this reason was used in the above-mentioned vaccination campaigns in Mozambique, Sudan, and Indonesia. Dukoral costs travellers more than US$10 per dose, and two doses two weeks apart are recommended for immunisation. Most tourists can afford this vaccine, and well-supported foundations can purchase this vaccine for interventions in larger populations. Yet Dukoral is likely to remain too expensive for governments of cholera-endemic regions to vaccinate at-risk populations. The technology on which Dukoral is based has previously been transferred to manufacturers in Vietnam, and has been more recently transferred to an Indian vaccine producer with certification to produce internationally licensed vaccines. There is therefore a justified hope that this vaccine candidate will become available internationally at an affordable price.medicine.plosjournals.org/perlserv/?r... In another case, a Dutch company, which holds the rights to a cholera vaccine, retains the rights in the developed world, but shares those rights with manufacturers in developing countries. The result is a cholera vaccine made in Vietnam that costs less than $1 a dose—and that includes delivery and the costs of an immunization campaign. There are a number of industries that can take advantage of this kind of tiered pricing to offer valuable medicine and technology to low-income people.www.gatesfoundation.org/MediaCenter/S... The first vaccine (Dukoral, licensed by SBL Vaccin, Sweden) consists of four batches of heat- or formalin-killed whole-cell V. cholerae O1, representing both serotypes (Inaba and Ogawa) and both biotypes (classical and El Tor), and added with purified recombinant cholera toxin subunit B (CTB). The whole cell/recombinant B subunit (WC/rBS) vaccine – given orally with buffer to neutralize stomach acidity – was found, in field trials in Bangladesh and Peru, to confer 80–90% protection during 6 months in all age groups after administration of 2 doses 1–2 weeks apart. In Bangladesh, protection declined in young children after 6 months, but was still about 60% in older children and adults after three years. The vaccine was also successfully used for mass vaccination in refugee camps in Uganda and in Dafur, Sudan. Efficacy in a demonstration study in Beira, Mozambique was shown to be close to 80% in a high HIV prevalence population. Because LT cross-reacts with CT, the vaccine also provides short-term protection against ETEC, which is of added benefit for travellers. A variant of the Dukoral vaccine containing no recombinant CTB-subunit has been produced and tested in Viet Nam. It is administered in two doses, one week apart. A field trial conducted in Nha-Trang, Viet Nam, showed an efficacy of 66% against V. cholerae El Tor after 8 months in all age groups tested. The vaccine has been licensed in Viet Nam and is currently being produced in Indonesia. A bivalent O1 and O139 whole-cell oral vaccine without CTB developed in Viet Nam was shown to be safe and immunogenic in both adults and children. This bivalent vaccine is currently the only existing vaccine against O139 serogroup infection.www.who.int/vaccine_research/diseases... The cholera vaccine is modelled on a widely available oral vaccine, Dukoral, which was developed in Sweden during the 1970s. But at several dollars a dose, Dukoral is too expensive for most developing countries. Vietnamese scientists licensed the technology in the early 1990s and formulated a cheaper version at about 20 cents per dose. With the IVI and Kolkata-based National Institute of Cholera and Enteric Diseases (NICED), Shantha Biotechnics, an Indian biotechnology company, is developing a local version of the Vietnamese vaccine and has procured regulatory clearances for the Kolkata trials. It has also secured the right to market the vaccine if it is approved, says Raman Rao, head of clinical research for Shantha.www.scidev.net/pdffiles/nature/436484...
Dirk R. Wijnen schreef:
Het tuig van het regime in Birma laat haar bevolking liever verrotten dan dat ze vacinatie accepteren.
Helaas idd. Constitutional referendum flouts human rights www.amnesty.org/en/for-media/press-re... In the wake of Cyclone Nargis, which has already killed tens of thousands of people and displaced around a million more, the government of Myanmar (formerly Burma) is deliberately impeding life-saving assistance. Its failure to open the borders to the massive relief efforts required, including expertise, will lead to further deaths and suffering for those affected by the cyclone. 8 mei 2008 Amnesty International roept de regering van Myanmar (Birma) op om onmiddellijk alle hulpverlening toe te laten voor slachtoffers van de verwoestende cycloon Nargis. De cycloon kostte aan tienduizenden mensen het leven en naar schatting een miljoen mensen werden dakloos. 'Mensenlevens gaan verloren doordat de overheid blijft vasthouden aan uitgebreide visumregelingen en donoren hun hulpverlening uitstellen uit angst dat het wordt doorgesluisd naar het leger', zegt Benjamin Zawacki, Myanmar-onderzoeker voor Amnesty. 'De regering moet het land open stellen voor buitenlandse hulpverleners en hen een veilige doorgang verlenen.' Tegenwerking Amnesty roept de regering van Myanmar op visa-aanvragen en douaneprocedures te versoepelen. Door tegenwerking kwam de internationale hulpverlening de afgelopen dagen maar moeizaam op gang en werd acute hulp aan het noodlijdende gebied vertraagd. Terwijl de eerste hulp Yangon (Rangoon) binnendruppelt heeft de overheid nog geen aanstalten gemaakt om de bevolking in de hardst getroffen gebieden te bereiken en van hulp te voorzien. Amnesty roept de regering op samen te werken met internationale hulpverleners en zonder restricties en zonder uitzondering hulp te verlenen aan iedereen die getroffen is door de cycloon. Ook moet de regering ervoor zorgen dat de naar schatting 1 miljoen mensen die dakloos zijn geraakt, worden opgevangen en toegang krijgen tot water, voedsel en medische verzorging Schrijf eens een “briefje”, hulp is steeds welkom! (Make my day!)www.amnesty.nl/in_actie_lopende_acties Yahoo…YaBoo Yahoo heeft toegegeven de privégegevens van journalist Shi Tao aan de Chinese autoriteiten te hebben verstrekt.www.amnesty.nl/in_actie_actie/21639
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
911,56
-0,04%
EUR/USD
1,0796
+0,06%
FTSE 100
8.419,53
+0,05%
Germany40^
18.710,10
-0,17%
Gold spot
2.344,38
+0,33%
NY-Nasdaq Composite
16.388,24
+0,29%
Stijgers
Dalers